Enhanced growth of hepatic hemangiomatosis in two adults after postmenopausal estrogen replacement therapy.
نویسندگان
چکیده
Liver hemangiomatosis is defined as extensive hemangioma in the liver. Although hemangioma is the most common hepatic tumor, diffuse hepatic hemangiomatosis is very rare. Most cases of hepatic hemangiomatosis are seen in infancy, but it is extremely rare in adults. This is the first report, showing the enhanced growth of diffuse hepatic hemangiomatosis after hormone replacement therapy. We report herein two unrelated women, 47 and 42 year-old, from different regions of Turkey, who admitted to hospital because of right abdominal pain with diffuse hepatic hemangiomatosis, developed after hormone replacement therapy for menopause. The patients were healthy, except for hemangiomatosis, and their physical examination, routine laboratory tests, and tumor marker levels were within normal limits. It should be noted that their abdominal ultrasonography was normal before hormone therapy, but ultrasonography on admission revealed numerous, ill defined, diffusely located liver nodules in both patients. Dynamic magnetic resonance imaging and scintigraphy have revealed that these lesions are compatible with hemangiomatosis. These results suggest that hepatic hemangiomatosis was induced by estrogen therapy. Consequently, hormone replacement therapy was discontinued, and the patients were followed up for 3 years. Their physical examination and blood chemistry, including liver enzymes, remained within normal range, and the follow-up examination with ultrasonography showed no changes in size of lesions. Because of the possible association of hemangioma with estrogen administration, decisions should be made carefully about estrogen therapy for patients who already have hemangioma, and the periodic ultrasonograpy examination should be planned to detect possible new growth of liver hemangiomatosis.
منابع مشابه
اثرات استروژن درمانی در زنان یائسه و ارتباط آن با سرطان پستان
Low levels of endogenous estrogens in postmenopausal women lead to several clinical problems. Some of these problems can be resolved by estrogen replacement therapy. The role of estrogen therapy in increasing the risk of breast cancer has not been well known yet. So, it was decided to study this controversial issue. In this study, 122 postmenopausal women, ranging in age from 46 to 61 years, we...
متن کاملDifferential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women.
OBJECTIVES We investigated whether the route of estrogen replacement therapy (ET) is the major determinant of C-reactive protein (CRP) in postmenopausal women. BACKGROUND Recent studies demonstrated that oral ET causes a sustained increase in CRP, implicating a proinflammatory effect. Because CRP is synthesized in the liver, we hypothesized that estrogen-induced CRP elevation is related to fi...
متن کاملDiffuse hepatic hemangiomatosis in an adult.
Diffuse hepatic hemangiomatosis without extrahepatic lesions is extremely rare in adults. A case of diffuse hepatic hemangiomatosis involving right lobe in a 50-year-old woman was presented. The hemangiomatosis was demonstrated by ultrasonography, computerized tomography (CT) and magnetic resonance image (MRI), and was confirmed histopathologically. Although diffuse hepatic hemangiomatosis is a...
متن کاملمقایسه تغییرات ماموگرافیک در دو نوع رژیم رایج هورمون درمانی جایگزین بعد از یائسگی
Background & Objective : Nowadays breast cancer is one of the most causes of female mortality. Mammography is a valuable method for early detection of breast cancer. Mammographic sensitivity depends on some factors such as age, breast tissue density, menopausal status, systemic disease, familial history of breast cancer and others. This study was designed to compare the effects of two regimen...
متن کاملThe route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.
The route of estrogen replacement therapy has a major impact on the growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis. Estrogen administration by the oral, but not the transdermal route, reduces IGF-I and increases GH levels in postmenopausal women. To investigate whether these perturbations have metabolic consequences, we compared the effects of 24 wk each of oral (Premarin 1.25 mg...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Tohoku journal of experimental medicine
دوره 210 3 شماره
صفحات -
تاریخ انتشار 2006